Welcome to our dedicated page for Arbutus Biopharm SEC filings (Ticker: ABUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arbutus Biopharma Corporation filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer with common shares without par value and a business focused on chronic hepatitis B therapeutics and lipid nanoparticle intellectual property. Form 8-K reports cover financial results, FDA Fast Track designation for imdusiran, material agreements, court orders, patent proceedings involving LNP delivery technology, and licensing or settlement matters with Genevant Sciences.
The company’s proxy materials describe annual shareholder meeting matters, board governance, executive compensation, voting procedures, and related corporate approvals. Its regulatory disclosures also connect clinical and regulatory updates for imdusiran with capital-structure, risk, intellectual-property, and operating-result reporting.
Arbutus Biopharma Corporation reported results from its 2026 Annual General and Special Meeting of Shareholders. Shareholders approved the new 2026 Omnibus Share and Incentive Plan, which authorizes issuance of an aggregate 16,300,000 common shares to support future equity-based compensation.
All director nominees were elected with strong majorities. Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Arbutus Biopharma Corporation: Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi report beneficial ownership of 18,557,543 common shares (9.4%) as of March 31, 2026. The shares are held by Two Seas Global (Master) Fund LP (13,904,953) and Two Seas LNP Opportunities (Master) Fund LP (4,652,590). The percent is calculated on 196,947,757 common shares outstanding as of March 31, 2026, per the issuer's Form 10-Q. The Reporting Persons state they have sole voting and sole dispositive power over the reported shares.
Arbutus Biopharma reported Q1 2026 revenue of $179.1M, up sharply due to recognizing $178.7M in license revenue tied to Genevant’s settlement with Moderna. This drove net income of $169.7M, compared with a loss in the prior-year quarter.
Total assets rose to $277.2M, including a $178.7M receivable from the noncontingent $950.0M Moderna settlement, while cash, cash equivalents and marketable securities were $95.2M with no debt. The company continues HBV programs for imdusiran and AB‑101 and is evaluating a potential return of capital after receiving its settlement share.
The FDA granted Fast Track designation to imdusiran for chronic hepatitis B, and Arbutus retains global rights to this RNAi candidate after ending its Qilu partnership. Litigation against Pfizer/BioNTech over LNP technology remains ongoing, and a separate contingent payment of up to $1.3B from Moderna depends on the outcome of a limited appeal.
Arbutus Biopharma reported a dramatic turnaround in the first quarter of 2026 driven by a major litigation settlement. Total revenue surged to $179.1 million, largely from $178.7 million of license revenue from Genevant tied to the Noncontingent Settlement Payment under its settlement with Moderna. This shift turned last year’s loss into net income of $169.7 million, compared with a net loss of $24.5 million in the prior-year quarter.
Cash, cash equivalents and marketable securities were $95.2 million as of March 31, 2026, modestly higher than at year-end. Research and development expenses fell to $4.1 million, reflecting workforce reductions, discontinued in-house research and lower clinical trial costs, while restructuring costs dropped to zero. The company also highlighted that the FDA granted Fast Track designation to its HBV RNAi therapeutic imdusiran, which may facilitate development and expedite review for chronic hepatitis B.
Whitefort Capital and related parties filed Amendment No. 4 to their Schedule 13D on Arbutus Biopharma Corp, reporting a significant ownership position. Whitefort Capital Master Fund directly owns 15,794,261 common shares, which is about 8.0% of Arbutus’s 196,939,679 shares outstanding as of March 30, 2026. The filing notes that these shares were acquired for an aggregate purchase price of approximately $41,324,734, funded from the fund’s working capital.
Various Whitefort entities and principals David Salanic and Joseph Kaplan may be deemed to share beneficial ownership of the same 15,794,261 shares through their roles as general partners and investment managers, though they expressly disclaim ownership of securities they do not directly hold. The filing also discloses a cash-settled total return swap between Whitefort Master Fund and Nomura Global Financial Products Inc. referencing 3,500,000 notional shares, or about 1.8% of outstanding shares, with a reference price of $4.2800 and maturity on October 29, 2029. Including these subject shares on an economic basis, Whitefort Master Fund’s total economic exposure is 19,294,261 shares, or roughly 9.8% of Arbutus’s outstanding stock, while they disclaim beneficial ownership and voting or dispositive power over the swap reference shares.
Arbutus Biopharma Corporation is asking shareholders to vote at its 2026 Annual General and Special Meeting on May 26, 2026 in Vancouver, BC. Holders of 196,939,679 common shares outstanding as of March 30, 2026 may vote.
Shareholders will elect five directors, consider a new 2026 Omnibus Share and Incentive Plan authorizing up to 16,300,000 common shares for equity awards, hold an advisory “say‑on‑pay” vote on named executive officer compensation, and approve the appointment of EY as independent registered public accounting firm for 2026. Materials are delivered primarily online, with voting available by mail, phone, Internet, or in person.
Whitefort Capital and related entities report beneficial ownership of 15,794,261 Arbutus Biopharma common shares, or approximately 8.1% of the class, in this amended Schedule 13D. The stake is based on 195,478,068 shares outstanding as of March 18, 2026.
The shares were purchased by Whitefort Capital Master Fund using working capital, which may include margin loans, for an aggregate purchase price of about $41,839,734 including brokerage commissions. Multiple Whitefort entities and Messrs. David Salanic and Joseph Kaplan may be deemed beneficial owners and expressly disclaim ownership of securities they do not directly own.
The amendment updates the ownership calculations and adds an exhibit listing all transactions in Arbutus Biopharma shares by the reporting persons over the prior 60 days, noting that these trades occurred in the open market unless otherwise indicated.
Arbutus Biopharma reported improved 2025 results and a transformative litigation settlement. Cash, cash equivalents and marketable securities were $91.5 million as of December 31, 2025, down from $122.6 million a year earlier as the company used $39.6 million in operating activities, partly offset by option exercises.
Total 2025 revenue rose to $14.1 million from $6.2 million, driven by recognition of previously deferred Qilu partnership revenue. Operating expenses fell sharply to $52.2 million from $82.5 million due to R&D and G&A cuts and restructuring, reducing net loss to $33.5 million, or $0.17 per share, versus $69.9 million, or $0.38 per share, in 2024.
Arbutus and Genevant reached a $2.25 billion global settlement with Moderna over lipid nanoparticle technology, including a $950 million noncontingent payment due in July 2026 and a $1.3 billion contingent payment tied to a Section 1498 appellate ruling. Arbutus will receive 20% of the noncontingent payment after litigation costs and also owns about 16% of Genevant. The company is evaluating a return of capital to shareholders after receiving its portion. Clinical updates include a total of 10 Phase 2a imdusiran patients achieving functional cure in chronic hepatitis B, with most maintaining durable responses.
Arbutus Biopharma Corporation is a clinical-stage biotech focused on chronic hepatitis B, developing imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. The company’s LNP delivery technology underpins major COVID-19 mRNA vaccines and is central to its strategy.
A key development is a settlement with Moderna, under which Moderna will pay an aggregate $950.0 million noncontingent lump sum to Arbutus and Genevant by July 8, 2026, plus a contingent lump sum of up to $1.3 billion tied to a limited appeal outcome. Arbutus is entitled to 20% of settlement proceeds (after litigation costs) under its Genevant license and also owns about 16% of Genevant’s common equity. The company is evaluating a potential return of capital to shareholders in the third quarter of 2026 after receiving its share of the noncontingent payment.
Arbutus continues patent litigation against Pfizer/BioNTech over alleged use of its LNP technology. It has restructured heavily, halting discovery efforts, closing its Warminster headquarters, and reducing its workforce by about 40% in 2024 and a further 57% in early 2025, incurring $12.9 million in one-time restructuring charges but significantly lowering net cash burn. As of June 30, 2025, non‑affiliate equity had an approximate market value of $472,133,611 based on a share price of $3.09, and as of March 18, 2026, there were 195,478,068 common shares outstanding.